Boston Scientific BSX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net sales of reportable segments by Business | ||||||
| Cardiovascular | $13.64B+2.6% | $13.29B+3.8% | $12.8B+4.8% | $12.22B+5.9% | $11.54B+6.4% | |
| MedSurg | $6.93B+1.3% | $6.84B+2.5% | $6.67B+3.6% | $6.44B+3.5% | $6.22B+3.2% | |
| Net Sales by Business | ||||||
| Cardiovascular | $13.67B+3.2% | $13.25B+4.2% | $12.72B+5.1% | $12.1B+6.2% | $11.4B+6.0% | |
| MedSurg | $6.95B+1.8% | $6.82B+2.8% | $6.64B+3.8% | $6.39B+3.8% | $6.16B+2.8% | |
| Total assets of reportable segments by Business | ||||||
| Cardiovascular | $31.55B+2.7% | $30.71B+3.1% | $29.79B— | —— | —— | |
| MedSurg | $13.84B+4.5% | $13.24B+2.3% | $12.94B— | —— | —— | |
| Other segment items by Business | ||||||
| Cardiovascular | $26M+4.0% | $25M+8.7% | $23M+4.5% | $22M+4.8% | $21M+10.5% | |
| MedSurg | $20M-4.8% | $21M-12.5% | $24M+26.3% | $19M+26.7% | $15M+7.1% | |
| Operating Income (Loss), Adjusted by Business | ||||||
| Cardiovascular | $4.38B+1.3% | $4.32B+3.3% | $4.18B+7.0% | $3.91B+7.8% | $3.62B+12.2% | |
| MedSurg | $2.27B-0.1% | $2.28B+0.5% | $2.26B+2.2% | $2.22B+3.6% | $2.14B+2.4% | |
| Selling, general and administrative expenses, percentage of net sale by Business | ||||||
| Cardiovascular | 82.5%-0.3pp | 82.8%— | —— | —— | —— | |
| Cost of products sold by Business | ||||||
| Cardiovascular | $4.09B+3.6% | $3.95B+3.5% | $3.81B+2.5% | $3.72B+5.5% | $3.53B+3.4% | |
| MedSurg | $1.96B+2.2% | $1.92B+3.9% | $1.85B+4.0% | $1.77B+4.0% | $1.71B+3.3% | |
| Cost of products sold, percentage of net sale by Business | ||||||
| Cardiovascular | 89.8%+1.2pp | 88.6%— | —— | —— | —— | |
| MedSurg | 84.2%+1.1pp | 83.1%+0.2pp | 82.9%+0.4pp | 82.5%+0.6pp | 81.9%+0.1pp | |
| Research and development expenses, percentage of net sale by Business | ||||||
| Cardiovascular | 29.7%+0.8pp | 28.9%+0.3pp | 28.6%+1.2pp | 27.4%+0.7pp | 26.7%-0.3pp | |
| MedSurg | 22.1%0.0pp | 22.1%0.0pp | 22.1%-0.1pp | 22.2%-0.6pp | 22.8%-0.1pp | |
| Selling, general and administrative expenses by Business | ||||||
| Cardiovascular | $3.78B+2.3% | $3.69B+3.2% | $3.58B+3.7% | $3.45B+3.4% | $3.33B+4.2% | |
| MedSurg | $2.17B+2.1% | $2.12B+3.8% | $2.04B+4.7% | $1.95B+3.3% | $1.89B+4.0% | |
| Impact of foreign currency fluctuations and purchase price and other adjustments by Business | ||||||
| MedSurg | $31M-41.5% | $53M+71.0% | $31M— | —— | —— | |
| Research and development expenses by Business | ||||||
| Cardiovascular | $1.37B+4.6% | $1.31B+8.2% | $1.21B+8.3% | $1.12B+8.1% | $1.03B+5.6% | |
| MedSurg | $513M+1.2% | $507M+2.0% | $497M+3.1% | $482M+1.3% | $476M+3.0% | |
| Goodwill by Business | ||||||
| Cardiovascular | $42.21B+1.7% | $41.49B+2.4% | $40.53B+2.1% | $39.68B+3.9% | $38.19B+2.2% | |
| MedSurg | $30.9B+1.6% | $30.42B+0.7% | $30.2B+8.4% | $27.86B+8.5% | $25.67B+9.2% | |
| Depreciation by Business | ||||||
| Cardiovascular | $366M+3.1% | $355M+4.1% | $341M+4.3% | $327M+3.8% | $315M+4.0% | |
| MedSurg | $117M+1.7% | $115M0.0% | $115M+1.8% | $113M+0.9% | $112M+2.8% | |
| Goodwill acquired by Business | ||||||
| Cardiovascular | $685M-23.0% | $890M+3.6% | $859M-39.6% | $1.42B+73.4% | $820M+33.3% | |
| MedSurg | $447M+158% | $173M-92.5% | $2.31B— | —— | —— | |
| Net Sales by Product | ||||||
| Cardiac Rhythm Management | $2.33B0.0% | $2.33B+0.9% | $2.31B+0.7% | $2.3B+0.6% | $2.28B+0.1% | |
| Electrophysiology | $3.5B+5.3% | $3.33B+7.8% | $3.08B+12.3% | $2.75B+17.7% | $2.33B+22.6% | |
| Endoscopy | $2.98B+2.2% | $2.92B+2.4% | $2.85B+2.5% | $2.78B+2.2% | $2.72B+1.2% | |
| Neuromodulation | $1.25B+3.9% | $1.2B+2.9% | $1.17B+2.2% | $1.14B+1.9% | $1.12B+1.4% | |
| Urology | $2.72B+0.5% | $2.71B+3.3% | $2.62B+6.1% | $2.47B+6.5% | $2.32B+5.5% | |
| Watchman | $2.04B+4.1% | $1.96B+6.6% | $1.84B+7.7% | $1.7B+6.7% | $1.6B+5.3% | |
| Net Sales by Geography | ||||||
| Asia-Pacific | $3.18B+3.3% | $3.08B+3.5% | $2.98B+4.1% | $2.86B+4.4% | $2.74B+2.0% | |
| Europe, Middle East and Africa | $3.54B+2.5% | $3.45B+3.1% | $3.35B+0.6% | $3.33B+1.7% | $3.27B+1.3% | |
| Latin America and Canada | $708M+4.4% | $678M+3.7% | $654M+2.5% | $638M+1.1% | $631M+1.0% | |
| U.S. | $13.19B+2.5% | $12.86B+4.0% | $12.37B+6.0% | $11.67B+6.9% | $10.91B+6.9% | |
| Long-Lived Assets by Geography | ||||||
| Costa Rica | $2.44B+3.5% | $2.36B+4.7% | $2.25B— | —— | —— | |
| Ireland | $2.91B+3.4% | $2.81B+4.4% | $2.69B— | —— | —— | |
| U.S. | $7.21B+6.3% | $6.78B+7.2% | $6.33B— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Boston Scientific break its business down?
- Boston Scientific (BSX) reports net sales of reportable segments by business across 2 parts — Cardiovascular and MedSurg. Each is extracted from the segment footnotes and tracked over time.
- Where does Boston Scientific's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Boston Scientific's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
